Guidelines on the use of therapeutic apheresis in clinical practice–evidence‐based approach from the writing committee of the American society for apheresis: the …

J Schwartz, A Padmanabhan, N Aqui… - Journal of clinical …, 2016 - Wiley Online Library
The American Society for Apheresis (ASFA) Journal of Clinical Apheresis (JCA) Special
Issue Writing Committee is charged with reviewing, updating, and categorizing indications …

An international consensus approach to the management of atypical hemolytic uremic syndrome in children

C Loirat, F Fakhouri, G Ariceta, N Besbas, M Bitzan… - Pediatric …, 2016 - Springer
Atypical hemolytic uremic syndrome (aHUS) emerged during the last decade as a disease
largely of complement dysregulation. This advance facilitated the development of novel …

Guidelines on the Use of therapeutic apheresis in clinical practice–Evidence‐Based approach from the Writing Committee of the American Society for Apheresis: The …

L Connelly‐Smith, CR Alquist, NA Aqui… - Journal of clinical …, 2023 - Wiley Online Library
Abstract The American Society for Apheresis (ASFA) Journal of Clinical Apheresis (JCA)
Special Issue Writing Committee is charged with reviewing, updating, and categorizing …

Guidelines on the use of therapeutic apheresis in clinical practice–evidence‐based approach from the Writing Committee of the American Society for Apheresis: the …

A Padmanabhan, L Connelly‐Smith… - Journal of clinical …, 2019 - Wiley Online Library
ABSTRACT The American Society for Apheresis (ASFA) Journal of Clinical Apheresis (JCA)
Special Issue Writing Committee is charged with reviewing, updating and categorizing …

[HTML][HTML] Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a “Kidney Disease: Improving Global Outcomes”(KDIGO) Controversies …

THJ Goodship, HT Cook, F Fakhouri, FC Fervenza… - Kidney international, 2017 - Elsevier
In both atypical hemolytic uremic syndrome (aHUS) and C3 glomerulopathy (C3G)
complement plays a primary role in disease pathogenesis. Herein we report the outcome of …

HUS and atypical HUS

TS Jokiranta - Blood, The Journal of the American Society of …, 2017 - ashpublications.org
Hemolytic uremic syndrome (HUS) is a thrombotic microangiopathy characterized by
intravascular hemolysis, thrombocytopenia, and acute kidney failure. HUS is usually …

Atypical aHUS: state of the art

CM Nester, T Barbour, SR de Cordoba… - Molecular …, 2015 - Elsevier
Tremendous advances in our understanding of the thrombotic microangiopathies (TMAs)
have revealed distinct disease mechanisms within this heterogeneous group of diseases. As …

[HTML][HTML] Clinical and genetic predictors of atypical hemolytic uremic syndrome phenotype and outcome

F Schaefer, G Ardissino, G Ariceta, F Fakhouri… - Kidney international, 2018 - Elsevier
Atypical hemolytic uremic syndrome (aHUS) is a rare, genetic, life-threatening disease. The
Global aHUS Registry collects real-world data on the natural history of the disease. Here we …

Haemolytic uraemic syndrome

D Karpman, S Loos, R Tati… - Journal of internal …, 2017 - Wiley Online Library
Haemolytic uraemic syndrome (HUS) is defined by the simultaneous occurrence of
nonimmune haemolytic anaemia, thrombocytopenia and acute renal failure. This leads to …

Hemolytic uremic syndrome

C Mele, G Remuzzi, M Noris - Seminars in immunopathology, 2014 - Springer
Hemolytic uremic syndrome (HUS) is a thrombotic microangiopathy defined by
thrombocytopenia, nonimmune microangiopathic hemolytic anemia, and acute renal failure …